{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T07:59:30Z","timestamp":1774771170361,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"am","delay-in-days":422,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.therap.2019.08.001","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T12:16:05Z","timestamp":1572264965000},"page":"471-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population"],"prefix":"10.1016","volume":"75","author":[{"given":"Dominique","family":"Hillaire-Buys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9gane","family":"Mousset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Allouchery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brahim","family":"Azzouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Babin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florelle","family":"Bellet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johana","family":"B\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Default","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"G\u00e9niaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Grandvuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Jantzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Lepelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Massy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Petitpain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Sanchez-Pena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Sassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Triquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Blanche","family":"Valnet-Rabier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwena\u00eblle","family":"Veyrac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Faillie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Zenut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2019.08.001_bib0150","author":"ANSM","year":"2016"},{"key":"10.1016\/j.therap.2019.08.001_bib0155","series-title":"La sp\u00e9cialit\u00e9 Ifosfamide EG\u00ae engendre-t-elle plus d\u2019enc\u00e9phalopathie que la sp\u00e9cialit\u00e9 Holoxan\u00ae\u00a0? \u00c9tude au CHU de Grenoble","author":"Gaudin","year":"2016"},{"key":"10.1016\/j.therap.2019.08.001_bib0160","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jcpt.12823","article-title":"Ifosfamide-induced encephalopathy: Brand-name (Holoxan\u00ae) vs generic formulation (Ifosfamide EG\u00ae)","volume":"44","author":"Chambord","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.therap.2019.08.001_bib0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont Salam\u00e9","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2019.08.001_bib0170","first-page":"13","article-title":"The neurotoxicity and pharmacokinetics of oral ifosfamide","volume":"4","author":"Highley","year":"2015","journal-title":"J Anal Oncol"},{"key":"10.1016\/j.therap.2019.08.001_bib0175","series-title":"Solutions of oxaphosphorins having improved stability and process for the preparation thereof United States. Asta Pharma Aktiengesellschaft (Frankfurt am Main, DE). United States patent 4952575","author":"Sauerbier","year":"1990"},{"key":"10.1016\/j.therap.2019.08.001_bib0180","series-title":"Aqueous ifosfamide composition. United States. Gensia Sicor Pharmaceuticals, Inc. (Irvine, CA, US). United States patent 6906047","author":"Mirejovsky","year":"2005"},{"key":"10.1016\/j.therap.2019.08.001_bib0185","series-title":"Aqueous ifosfamide compositions for parenteral administration and a process for their preparations. United States Bharat Serums & Vaccines Ltd. (Maharashtra, IN). United States patent 7199111","author":"Daftary","year":"2007"},{"key":"10.1016\/j.therap.2019.08.001_bib0190","first-page":"921","article-title":"Unexpected toxicity in patients treated with iphosphamide","volume":"32","author":"Van Dyk","year":"1972","journal-title":"Cancer Res"},{"key":"10.1016\/j.therap.2019.08.001_bib0195","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/oxfordjournals.annonc.a058327","article-title":"Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer","volume":"3","author":"Manegold","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1016\/j.therap.2019.08.001_bib0200","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/oxfordjournals.annonc.a058317","article-title":"The enigma of ifosfamide encephalopathy","volume":"3","author":"Cerny","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1016\/j.therap.2019.08.001_bib0205","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(86)92227-0","article-title":"Dechloroethylation of ifosfamide and neurotoxicity","volume":"2","author":"Goren","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2019.08.001_bib0210","first-page":"3247","article-title":"Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide, in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide","volume":"16","author":"Kaijser","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1016\/j.therap.2019.08.001_bib0215","first-page":"193","article-title":"Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats","volume":"26","author":"Visarius","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.therap.2019.08.001_bib0220","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0022-3565(24)29242-9","article-title":"Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)\/kainite receptors and induce cellular acidification in mouse cortical neurons","volume":"299","author":"Chatton","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.therap.2019.08.001_bib0225","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s002280050102","article-title":"Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy","volume":"50","author":"K\u00fcpfer","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.08.001_bib0230","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0140-6736(94)91839-2","article-title":"Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue","volume":"343","author":"K\u00fcpfer","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2019.08.001_bib0235","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/03602530500364023","article-title":"Metabolism and transport of oxazaphosphorines and the clinical implications","volume":"37","author":"Zhang","year":"2005","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.therap.2019.08.001_bib0240","first-page":"1941","article-title":"Pharmacokinetics of ifosfamide and some metabolites in children","volume":"18","author":"Kaijser","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.therap.2019.08.001_bib0245","first-page":"1985","article-title":"Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children","volume":"3","author":"Yule","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.therap.2019.08.001_bib0250","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200140010-00004","article-title":"Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites","volume":"40","author":"Kerbusch","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.therap.2019.08.001_bib0255","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/bdd.257","article-title":"Distribution of ifosfamide and metabolites between plasma and erythrocytes","volume":"22","author":"Kerbusch","year":"2001","journal-title":"Biopharm Drug Disp"},{"key":"10.1016\/j.therap.2019.08.001_bib0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1078155208093930","article-title":"Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant","volume":"14","author":"Howell","year":"2008","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.therap.2019.08.001_bib0265","first-page":"137","article-title":"Aprepitant-associated ifosfamide neurotoxicity","volume":"16","author":"Hansen","year":"2010","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.therap.2019.08.001_bib0270","first-page":"1","article-title":"Incidence of encephalopathy and associeted risk factors in two different ifosfamide formulations, a retrospective bicentric study. 21st Annual Meeting of French Society of Pharmacology and Therapeutics, 19\u201321 April 2017, Rouen, France","volume":"31","author":"Chenaf","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.08.001_bib0275","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/1078155216631408","article-title":"Drug interactions with aprepitant and fosaprepitant: review of literature and implications for clinical practice","volume":"23","author":"Dushenkov","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.therap.2019.08.001_bib0280","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/bcp.13322","article-title":"Aprepitant and fosaprepitant drug interactions: a systematic review","volume":"83","author":"Patel","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.08.001_bib0285","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00776-009-1431-y","article-title":"Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors","volume":"15","author":"Tajino","year":"2010","journal-title":"J Orthop Sci"},{"key":"10.1016\/j.therap.2019.08.001_bib0290","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1078155214527143","article-title":"An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center","volume":"21","author":"Szabatura","year":"2015","journal-title":"J Oncol Pharm Pract"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719301532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719301532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:00Z","timestamp":1758567240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595719301532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0040595719301532"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2019.08.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2019.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}